No description available.

Die Technik der intravitrealen Gentamicin Injektion darzulegen, die Auswirkungen dieser auf die klinischen Symptome von Uveitiden, sowie die möglichen unmittelbaren Komplikationen (innerhalb von 24 Stunden) und längerfristigen Komplikationen (30 bis 780 Tage) die mit dieser Technik verbunden sein können, zu beschreiben. Zusätzlich wurde der okuläre und systemische Leptospiren- Status ermittelt und der Einfluss dieser auf das Behandlungsergebnis untersucht.:Table of Contents 1 INTRODUCTION 1 2 LITERATURE OVERVIEW 2 2.1 Etiology and pathogenesis 2 2.1.1 Proposed etiologies 2 2.1.2 ERU: an immune mediated disease 3 2.2 Leptospirosis and ERU 4 2.2.1 Genetic predisposition for ERU 6 2.3 Definition of ERU 7 2.3.1 Classification and syndromes 7 2.3.2 Clinical symptoms 8 2.4 Diagnostic testing for ERU (Leptospira) 8 2.4.1 Sample collection (aqueous humor, vitreous humor, serum) 8 2.4.2 Methodology 9 2.4.2.1 Microagglutination test (MAT) 9 2.4.2.2 Polymerase chain reaction (PCR) 10 2.4.2.3 Cultures 10 2.5 Treatment of ERU 10 2.5.1 Medical management 10 2.5.2 Intravitreal and suprachoroidal injections 11 2.5.2.1 Intravitreal rapamycin injections 11 2.5.2.2 Intravitreal triamcinolone injections 11 2.5.2.3 Suprachoroidal triamcinolone injections 12 2.5.2.4 Low-dose intravitreal gentamicin injections 12 2.5.3 Surgical procedures 13 2.5.3.1 Suprachoroidal cyclosporine implants 13 2.5.3.2 Pars plana vitrectomy 14 3 PUBLICATIONS 16 3.1 Intravitreal injection of low-dose gentamicin for the treatment of recurrent or persistent uveitis in horses: Preliminary results 16 3.2 Medical and Surgical Management of Equine Recurrent Uveitis 29 4 DISCUSSION 47 5 ZUSAMMENFASSUNG 51 6 SUMMARY 52 7 REFERENCES 53 / To describe the intravitreal gentamicin injection technique, report the effects of the injection on the clinical signs of uveitis and to describe the associated peri-injection (within 24 hours) and post-injection complications (30 to 780 days). Additionally, evaluation of the systemic and ocular Leptospira status and its effects on the treatment outcome was performed.:Table of Contents 1 INTRODUCTION 1 2 LITERATURE OVERVIEW 2 2.1 Etiology and pathogenesis 2 2.1.1 Proposed etiologies 2 2.1.2 ERU: an immune mediated disease 3 2.2 Leptospirosis and ERU 4 2.2.1 Genetic predisposition for ERU 6 2.3 Definition of ERU 7 2.3.1 Classification and syndromes 7 2.3.2 Clinical symptoms 8 2.4 Diagnostic testing for ERU (Leptospira) 8 2.4.1 Sample collection (aqueous humor, vitreous humor, serum) 8 2.4.2 Methodology 9 2.4.2.1 Microagglutination test (MAT) 9 2.4.2.2 Polymerase chain reaction (PCR) 10 2.4.2.3 Cultures 10 2.5 Treatment of ERU 10 2.5.1 Medical management 10 2.5.2 Intravitreal and suprachoroidal injections 11 2.5.2.1 Intravitreal rapamycin injections 11 2.5.2.2 Intravitreal triamcinolone injections 11 2.5.2.3 Suprachoroidal triamcinolone injections 12 2.5.2.4 Low-dose intravitreal gentamicin injections 12 2.5.3 Surgical procedures 13 2.5.3.1 Suprachoroidal cyclosporine implants 13 2.5.3.2 Pars plana vitrectomy 14 3 PUBLICATIONS 16 3.1 Intravitreal injection of low-dose gentamicin for the treatment of recurrent or persistent uveitis in horses: Preliminary results 16 3.2 Medical and Surgical Management of Equine Recurrent Uveitis 29 4 DISCUSSION 47 5 ZUSAMMENFASSUNG 51 6 SUMMARY 52 7 REFERENCES 53